FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4365478875> ?p ?o ?g. }

• W4365478875 endingPage "1082" @default.
• W4365478875 startingPage "1075" @default.
• W4365478875 abstract "Patients with antibody deficiencies often receive maintenance treatment with donor plasma-derived immunoglobulin (Ig) preparations to decrease the incidence and severity of infections. We have previously shown that IgG antibodies to the original SARS-CoV-2 strain were not consistently present in off-the-shelf Ig batches produced up to approximately 18 months after the first identified case of COVID-19 in the USA and that Ig batches with anti-SARS-CoV-2 IgG primarily contained vaccine-induced spike specific antibodies. This study aimed to investigate the degree of cross-reactivity between vaccine-induced anti-SARS-CoV-2 antibodies against Wuhan strain and subsequent viral variants.Samples were collected from 74 Ig batches supplied by three different commercial manufacturers. All batches were used at the Immunodeficiency Unit at the Karolinska University Hospital from the start of the SARS-CoV-2 pandemic until September 2022. Antibody quantity and potential to neutralize virus entry into host cells were assessed against the original SARS-CoV-2 Wuhan strain and the following nine variants: Alpha, Beta, Delta, IHU, and the Omicron BA.1, BA.1.1, BA.1 with spike mutation L452R, BA.2, and BA.3.Ig batches produced approximately 18 months after the SARS-CoV-2 outbreak (from around July 2021) and later consistently contained high quantities of antibodies that bind the Wuhan strain. The Ig batches had overall low reactivity to the SARS-CoV-2 nucleocapsid, which implies that plasma donor spike IgG essentially is the result of vaccination. We assessed the degree of cross-reactivity towards each virus variant by plotting the variant/Wuhan strain ratio, which was consistent regardless of production date, suggesting cross-reactivity with vaccine-induced antibodies rather than virus exposure in the plasma donor population. Viral variants that emerged later during the pandemic systematically had a lower reactivity ratio, except for the Delta and IHU variants. The Ig batches displayed markedly low neutralizing potential towards the Beta variant and all tested Omicron variants.Commercial Ig batches currently contain large quantities of SARS-CoV-2 vaccine-induced antibodies. Cross-reactivity with variant strains is evident but varies, with markedly low neutralizing potential observed against Omicron variants." @default.
• W4365478875 created "2023-04-15" @default.
• W4365478875 creator A5029541730 @default.
• W4365478875 creator A5037433972 @default.
• W4365478875 creator A5041138185 @default.
• W4365478875 creator A5043318824 @default.
• W4365478875 creator A5057116894 @default.
• W4365478875 creator A5066012504 @default.
• W4365478875 creator A5074350862 @default.
• W4365478875 creator A5091546357 @default.
• W4365478875 date "2023-04-14" @default.
• W4365478875 modified "2023-10-16" @default.
• W4365478875 title "SARS-CoV-2 Antibodies in Commercial Immunoglobulin Products Show Markedly Reduced Cross-reactivities Against Omicron Variants" @default.
• W4365478875 cites W1487079135 @default.
• W4365478875 cites W3111445693 @default.
• W4365478875 cites W3130059284 @default.
• W4365478875 cites W3133980772 @default.
• W4365478875 cites W3152531891 @default.
• W4365478875 cites W3184226105 @default.
• W4365478875 cites W3217201218 @default.
• W4365478875 cites W4206106358 @default.
• W4365478875 cites W4212790397 @default.
• W4365478875 cites W4220874202 @default.
• W4365478875 cites W4223612665 @default.
• W4365478875 cites W4280502978 @default.
• W4365478875 cites W4284889304 @default.
• W4365478875 cites W4285808848 @default.
• W4365478875 cites W4285993171 @default.
• W4365478875 cites W4289261677 @default.
• W4365478875 cites W4294316470 @default.
• W4365478875 cites W4296026861 @default.
• W4365478875 cites W4301399119 @default.
• W4365478875 cites W4312127820 @default.
• W4365478875 cites W4313471163 @default.
• W4365478875 cites W4315753264 @default.
• W4365478875 cites W4317870853 @default.
• W4365478875 doi "https://doi.org/10.1007/s10875-023-01486-8" @default.
• W4365478875 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37058198" @default.
• W4365478875 hasPublicationYear "2023" @default.
• W4365478875 type Work @default.
• W4365478875 citedByCount "0" @default.
• W4365478875 crossrefType "journal-article" @default.
• W4365478875 hasAuthorship W4365478875A5029541730 @default.
• W4365478875 hasAuthorship W4365478875A5037433972 @default.
• W4365478875 hasAuthorship W4365478875A5041138185 @default.
• W4365478875 hasAuthorship W4365478875A5043318824 @default.
• W4365478875 hasAuthorship W4365478875A5057116894 @default.
• W4365478875 hasAuthorship W4365478875A5066012504 @default.
• W4365478875 hasAuthorship W4365478875A5074350862 @default.
• W4365478875 hasAuthorship W4365478875A5091546357 @default.
• W4365478875 hasBestOaLocation W43654788751 @default.
• W4365478875 hasConcept C116675565 @default.
• W4365478875 hasConcept C126322002 @default.
• W4365478875 hasConcept C159047783 @default.
• W4365478875 hasConcept C159654299 @default.
• W4365478875 hasConcept C185592680 @default.
• W4365478875 hasConcept C203014093 @default.
• W4365478875 hasConcept C2522874641 @default.
• W4365478875 hasConcept C2779134260 @default.
• W4365478875 hasConcept C2779142602 @default.
• W4365478875 hasConcept C2780898057 @default.
• W4365478875 hasConcept C3007834351 @default.
• W4365478875 hasConcept C3008058167 @default.
• W4365478875 hasConcept C3020064264 @default.
• W4365478875 hasConcept C524204448 @default.
• W4365478875 hasConcept C71924100 @default.
• W4365478875 hasConceptScore W4365478875C116675565 @default.
• W4365478875 hasConceptScore W4365478875C126322002 @default.
• W4365478875 hasConceptScore W4365478875C159047783 @default.
• W4365478875 hasConceptScore W4365478875C159654299 @default.
• W4365478875 hasConceptScore W4365478875C185592680 @default.
• W4365478875 hasConceptScore W4365478875C203014093 @default.
• W4365478875 hasConceptScore W4365478875C2522874641 @default.
• W4365478875 hasConceptScore W4365478875C2779134260 @default.
• W4365478875 hasConceptScore W4365478875C2779142602 @default.
• W4365478875 hasConceptScore W4365478875C2780898057 @default.
• W4365478875 hasConceptScore W4365478875C3007834351 @default.
• W4365478875 hasConceptScore W4365478875C3008058167 @default.
• W4365478875 hasConceptScore W4365478875C3020064264 @default.
• W4365478875 hasConceptScore W4365478875C524204448 @default.
• W4365478875 hasConceptScore W4365478875C71924100 @default.
• W4365478875 hasFunder F4320321491 @default.
• W4365478875 hasFunder F4320322315 @default.
• W4365478875 hasFunder F4320322327 @default.
• W4365478875 hasFunder F4320322570 @default.
• W4365478875 hasFunder F4320322581 @default.
• W4365478875 hasIssue "6" @default.
• W4365478875 hasLocation W43654788751 @default.
• W4365478875 hasLocation W43654788752 @default.
• W4365478875 hasLocation W43654788753 @default.
• W4365478875 hasOpenAccess W4365478875 @default.
• W4365478875 hasPrimaryLocation W43654788751 @default.
• W4365478875 hasRelatedWork W2139983200 @default.
• W4365478875 hasRelatedWork W2435535700 @default.
• W4365478875 hasRelatedWork W3014337446 @default.
• W4365478875 hasRelatedWork W3031696803 @default.
• W4365478875 hasRelatedWork W3127693599 @default.
• W4365478875 hasRelatedWork W3196541986 @default.

• next